Effectiveness, safety, and pharmacoeconomic profile of Sophora flavescens film in the treatment of postpartum vaginal dysbiosis: a non-randomized controlled trial.

Researchers in China studied whether a traditional Chinese herbal film made from Sophora flavescens (a medicinal plant containing matrine) could help women experiencing vaginal imbalance after childbirth. This condition, called postpartum vaginal dysbiosis, occurs when the natural bacteria in the vagina become unbalanced, leading to discomfort and inflammation.

The study involved 126 women who were 6-8 weeks postpartum. Half received standard treatment plus the herbal film applied topically, while the other half received standard treatment alone. Women who used the herbal film showed significantly better recovery of their vaginal health. Specifically, they had improved vaginal health scores, reduced inflammation, and better overall quality of life compared to those receiving standard treatment only.

The herbal film was well-tolerated, with only mild, temporary local irritation reported in some cases and no serious side effects. The treatment was also found to be cost-effective, adding only about ¥244 (approximately $34 USD) per 1% improvement in treatment success.

While these results are promising for postpartum vaginal health, it's important to note this was not a randomized controlled trial, which is considered the gold standard for medical research. The researchers acknowledge that larger, more rigorous studies are needed to confirm these findings.

For women experiencing postpartum vaginal issues, this study suggests that traditional Chinese herbal treatments may offer benefits when combined with conventional care. If you're interested in exploring traditional Chinese medicine options including acupuncture for postpartum recovery, consult with a licensed acupuncturist or qualified TCM practitioner who can provide personalized care.

This open-label, non-randomized controlled trial (n=126; 63 per group) evaluated Sophora flavescens film (SFF) containing matrine as adjunctive therapy for postpartum vaginal dysbiosis in women 6-8 weeks postdelivery. Primary outcome was composite vaginal ecosystem effectiveness; secondary outcomes included Vaginal Health Index Score (VHIS), Vaginal Inflammation Score (VIS), and EQ-5D-5L quality of life measures. Statistical analysis employed logistic regression and ANCOVA with DAG-based confounder adjustment.

Results demonstrated significantly higher overall effectiveness in the SFF group (adjusted OR=3.68, 95% CI: 1.49-9.09, P=0.005). Secondary outcomes showed clinically meaningful improvements: VHIS (MD=2.420, η²=0.332), VIS (MD=-0.425, η²=0.109), and EQ-5D-5L (MD=0.029, η²=0.150), all P<0.001. Only mild, self-limiting local irritation was reported. ICER indicated ¥244.23 per 1% effectiveness increase.

Clinical implications: SFF demonstrates potential as safe, cost-effective adjunctive therapy for postpartum vaginal dysbiosis. Non-randomized design limits causality assessment; multicenter RCTs warranted for confirmation.